Sökning: onr:"swepub:oai:DiVA.org:uu-279079" >
Dose Reduction of C...
Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
-
Martial, Lisa C (författare)
-
Brüggemann, Roger J M (författare)
-
Schouten, Jeroen A (författare)
-
visa fler...
-
van Leeuwen, Henk J (författare)
-
van Zanten, Arthur R (författare)
-
de Lange, Dylan W (författare)
-
Muilwijk, Eline W (författare)
-
Verweij, Paul E (författare)
-
Burger, David M (författare)
-
Aarnoutse, Rob E (författare)
-
Pickkers, Peter (författare)
-
- Dorlo, Thomas P C (författare)
- Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Pharmacometrics Group
-
visa färre...
-
(creator_code:org_t)
- 2015-12-09
- 2016
- Engelska.
-
Ingår i: Clinical Pharmacokinetics. - : Springer Science and Business Media LLC. - 0312-5963 .- 1179-1926. ; 55:6, s. 723-733
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND AND OBJECTIVES: Caspofungin is an echinocandin antifungal agent used as first-line therapy for the treatment of invasive candidiasis. The maintenance dose is adapted to body weight (BW) or liver function (Child-Pugh score B or C). We aimed to study the pharmacokinetics of caspofungin and assess pharmacokinetic target attainment for various dosing strategies.METHODS: Caspofungin pharmacokinetic data from 21 intensive care unit (ICU) patients was available. A population pharmacokinetic model was developed. Various dosing regimens (loading dose/maintenance dose) were simulated: licensed regimens (I) 70/50 mg (for BW <80 kg) or 70/70 mg (for BW >80 kg); and (II) 70/35 mg (for Child-Pugh score B); and adapted regimens (III) 100/50 mg (for Child-Pugh score B); (IV) 100/70 mg; and (V) 100/100 mg. Target attainment based on a preclinical pharmacokinetic target for Candida albicans was assessed for relevant minimal inhibitory concentrations (MICs).RESULTS: A two-compartment model best fitted the data. Clearance was 0.55 L/h and the apparent volumes of distribution in the central and peripheral compartments were 8.9 and 5.0 L, respectively. The median area under the plasma concentration-time curve from time zero to 24 h on day 14 for regimens I-V were 105, 65, 93, 130, and 186 mg·h/L, respectively. Pharmacokinetic target attainment was 100 % (MIC 0.03 µg/mL) irrespective of dosing regimen but decreased to (I) 47 %, (II) 14 %, (III) 36 %, (IV) 69 %, and (V) 94 % for MIC 0.125 µg/mL.CONCLUSION: The caspofungin maintenance dose should not be reduced in non-cirrhotic ICU patients based on the Child-Pugh score if this classification is driven by hypoalbuminemia as it results in significantly lower exposure. A higher maintenance dose of 70 mg in ICU patients results in target attainment of >90 % of the ICU patients with species with an MIC of up to 0.125 µg/mL.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Martial, Lisa C
-
Brüggemann, Roge ...
-
Schouten, Jeroen ...
-
van Leeuwen, Hen ...
-
van Zanten, Arth ...
-
de Lange, Dylan ...
-
visa fler...
-
Muilwijk, Eline ...
-
Verweij, Paul E
-
Burger, David M
-
Aarnoutse, Rob E
-
Pickkers, Peter
-
Dorlo, Thomas P ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Farmakologi och ...
- Artiklar i publikationen
-
Clinical Pharmac ...
- Av lärosätet
-
Uppsala universitet